ClinicalTrials.gg
WithdrawnNCT05432960Updated Nov 15, 2024

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

A Phase 3 interventional study of RPH-104 and Placebo in Adult-Onset Still's Disease and AOSD, sponsored by R-Pharm International, LLC. Withdrawn at 4 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study halted according to the Sponsor's descision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's Disease (AOSD). Furthermore, the study is scheduled to investigate pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RPH-104.

Read the detailed description

The overall study will include the following periods:

  • screening period (up to 4 weeks) - the evaluation of patient compliance with inclusion/exclusion criteria.
  • run-in period (29 weeks) - open-label administration of RPH-104 160 mg on Day 0, Day 7, Day 21 and then Q2W SC with gradual dose reduction with further complete withdrawal (if applicable) of the previous therapy with AOSD.

Baseline characteristics will be evaluated on Study Day 0. Assessment of efficacy (treatment response) and safety will be performed at Visit 2 (Day 7), Visit 3 (Day 21), Visit 4 (Day 35) and then every 4 weeks during the run-in period. A response to therapy during this period is the achievement of low activity/inactive disease including no exacerbations of AOSD.

The subjects who achieve and preserve low activity/inactive disease for at least 8 weeks under mono therapy with RPH-104 (i. e. previous therapy has been permanently discontinued) or combination of RPH-104 and GC at dose achieved in reduction (7.5 mg/day or less), stable for at least 4 weeks can be switched to the randomized withdrawal period.

  • randomized withdrawal period (24 weeks) - blind SC administration of 160 mg of RPH-104 / equivalent volume of placebo Q2W depending on the distribution group in randomization; if the disease exacerbates during this period, a subject can be switched from placebo into a 53-week open-label therapy with RPH-104 (can be continued for 6 months in case of exacerbation as decided by the investigator).

Efficacy and safety assessment during the randomized withdrawal period will be performed every 4 weeks. During this period the investigational product/placebo will be administered to the subjects every 2 weeks - at visits to the study site - by the qualified medical staff (or a subject monitored by the staff) or at home by the subjects themselves. In case of self-administration of the investigational product/placebo by a subject during the randomized withdrawal period, additional conditions will be created to prevent from unblinding.

  • safety follow-up period (8 weeks). The subjects who completed the randomized withdrawal period and the subjects who completed 53 weeks of resumed therapy (if applicable) and the subjects whose therapy was continued as decided by the investigator for 6 months after exacerbation in the randomized withdrawal period (for subjects from the investigational product group), or exacerbation during the resumed therapy - after the end of therapy will be switched into the safety follow-up period during which they will have to visit the study site for assessments in 2 and 8 weeks after the last dosing with the investigational products, thereafter their participation in the study will be considered completed.

The subjects who terminated therapy with RPH-104 early (for any reasons in any treatment period) will be prescribed with other products selected by the investigator and will have to make safety follow-up visits in 2 and 8 weeks after the last dosing with the investigational product.

Maximum possible duration of study per patient will be 144 weeks.

It is planned to randomize totally 36 patients with AOSD in the study (18 patients per group). Given potential withdrawal at the screening and during the run-in period, the number of screened patients (who signed informed consent) will be totally about 53 screened patients.

02

Conditions studied

  • Adult-Onset Still's Disease
  • AOSD

Keywords

  • RPH-104
  • subcutaneous
03

In context

Still's Disease, Adult-Onset

23 studies on the registry are indexed under Still's Disease, Adult-Onset; 5 are open to participants now.

Browse Still's Disease, Adult-Onset studies →

Lead sponsor

R-Pharm International, LLC is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of voluntarily signed and dated Form to participate in this study.
  2. Definite diagnosis of Still's disease made on the basis of Yamaguchi diagnostic criteria (Yamaguchi M., 1992).
  3. A patient with AOSD (with inactive disease / low disease activity / exacerbation).
  4. In case of current GCs administration, their doses should be stable for at least 2 weeks prior to Day 0. Maximum acceptable dose calculated as 1 mg/kg/day is up to 60 mg/day.
  5. In case of on-going methotrexate (MTX) administration, the dose should be stable for at least 4 weeks prior to Day 0. Maximum acceptable dose is 30 mg/week. In case of withdrawal of previous MTX administration, it should be made at least 4 weeks before Day 0.
  6. Ability and willingness of the subject, according to the reasonable investigator's judgment, to attend the study site at all scheduled visits, undergo the study procedures and follow the protocol requirements including subcutaneous injections by qualified site personnel.
  7. Consent of female subjects with , defined as all females with physiological potential to conceive (except for those with absolute termination of menses to be determined retrospectively after 12 months of natural amenorrhea, i. e. amenorrhea with relevant clinical status, e. g. appropriate age) to use highly effective throughout the study starting from the screening (signed Informed Consent Form) and for at least 8 weeks after discontinuation of the study product administration; and negative pregnancy test (serum test for chorionic gonadotropin).

OR Consent of male subjects leading active sexual life to use highly efficient contraceptive measures throughout the study starting from the moment of signing the Informed Consent Form and for at least 8 weeks after the study product discontinuation.

Highly effective contraceptive method is defined as follows:

  • complete abstinence: if complies with patients' preferable and habitual way of life. Periodic abstinence (e. g. calendar, ovulation, symptothermal, post-ovulation methods) and interrupted intercourse are not acceptable contraception methods;
  • surgical intervention for female sterilization: bilateral ovariectomy (with/without hysterectomy) or tubal ligation at least 6 weeks prior to the study therapy initiation. In case of ovariectomy only, the female reproductive status should be verified by further hormonal test;
  • surgical intervention for male sterilization (with a relevant documented lack of the sperm in the post-vasectomy ejaculate) at least 6 months prior to screening. For female subjects, a vasectomized sexual partner should be the only partner;
  • combination of any two of the following methods (a+b or a+c or b+c):

    1. oral, injection or implanted hormonal contraceptives; in case of oral contraceptives, the female subjects should administer the same product for at least 3 months prior to the study therapy;
    2. intrauterine device or contraceptive system;
    3. barrier contraception methods: a condom or occlusive cap (diaphragm or cervical cap/ vaginal fornix cap) with a spermicidal foam/ gel/ film/ cream/ vaginal suppository.

Exclusion criteria

Exclusion Criteria:

  1. to the product (RPH-104) and/or its ingredients/.
  2. Previous administration of:

    • rilonacept - less than 6 weeks prior to Day 0 of the study;
    • canakinumab - less than 12 weeks prior to Day 0 of the study;
    • anakinra - less than 1 week prior to Day 0 of the study;
    • tumor necrosis factor alpha (TNF-a) antagonists, Interleukin 6 (IL-6) inhibitors - less than 12 weeks prior to Day 0 of the study;
    • Janus kinase inhibitors - less than 1 week prior to Day 0 of the study;
    • (azathioprine, cyclosporin, mycophenolate mofetil, tacrolimus, sirolimus, mercaptopurine, etc., except for methotrexate) - less than 24 weeks prior to Study Day 0;
    • pulse therapy with GC (e. g., methylprednisolone 250-1000 mg/day intravenously or dexamethasone equivalent for 3 days) - less than 4 weeks (from the end of pulse therapy) to Study Day 0;
    • any other biological product - less than 5 half-lives prior to Study Day 0.
  3. Administration of live (attenuated) vaccine less than 3 months prior to Visit 1 (study treatment period initiation) and/or necessity to use such vaccine within 3 months after the study therapy discontinuation. include viral vaccines against: measles, rubella, parotitis, varicella, rotavirus, influenza (as nasal spray), yellow fever, poliomyelitis (oral polio-vaccine), tuberculosis vaccine (BCG), typhoid (oral typhoid fever vaccine) and camp fever (epidemic typhoid vaccine). Immunocompetent family members should refuse to use oral polio-vaccine throughout the subject's participation in the study.
  4. Conditions or signs which, according to the investigator, suggest impaired (reduced) immune response and/or significantly increase the risk of immunomodulating therapy including (but not limited to):

    • 4.1. active bacterial, fungal, viral or protozoal infection at screening onset;
    • 4.2. opportunistic infections and/or Kaposi's sarcoma at the screening period onset;
    • 4.3. chronic bacterial, fungal or viral infection requiring systemic therapy with parenteral products at the main screening period onset;
    • 4.4. human immunodeficiency viruses (), or C.
  5. Active infection of M. Tuberculosis, as per examination results: positive QuantiFERON-TB/SPOT.TB test at screening, chest X-ray findings confirming pulmonary tuberculosis during screening.

    * At discretion of certified tuberculosis specialist or pulmonologist specialized in diagnosing and treatment of tuberculosis, a patient with latent tuberculosis can be included in the study during the preventative treatment of latent tuberculosis infection with isoniazid or rifampicin (the choice of preventive therapy is made by a phthisiatrician, taking into account , drug interactions and risks of adverse reactions in a particular patient).

  6. Any other relevant concomitant diseases (cardiovascular, nervous, endocrine, urinary, gastrointestinal, hepatic disorders, hemostatic disorders, other diseases, etc.) or conditions which, according to the investigator's judgment, may affect the subject's participation or well-being in the study and/or distort assessment of the study results.
  7. History of organ transplantation or necessity in transplantation at the screening onset.
  8. Any during the screening period or for 5 years before screening except for non- basal cell and squamous cell skin cancer after total resection or in situ carcinoma of any type after total resection.
  9. Psychiatric disorders which, according to the justified investigator's judgment, may affect the subject participation in the study and his/her ability to follow the protocol procedures.
  10. Pregnancy or breast-feeding.
  11. History of alcohol or psychoactive substances abuse, according to the investigator's evaluation.
  12. Severe renal failure: Cockroft-Gault (ClCr) \< 30 mL/min.
  13. Any of the deviations in the laboratory tests below:

    • \< 1.5 х 10\^9/L;
    • white blood cells (WBC) count \< 3.5 х 10\^9/L;
    • count \< 100 х 10\^9/L;
    • level ≤ 80 g/L;
    • (HbA1c) ≥ 8 %);
    • (ALT) and/or aspartate aminotransferase (AST) > 8.0 x (ULN);
    • AST and/or AST > 3 x ULN with increased > 1.5 x ULN;
    • bilirubin > 1.5 x ULN (except for confirmed Gilbert's disease).
  14. Uncontrolled diabetes mellitus.
  15. Concomitant participation in other clinical studies at the screening onset or administration of any unauthorized (investigational) products less than 4 weeks or 5 half-life periods (whichever is longer) before Visit 1 (treatment initiation in the study).
  16. Macrophage activation syndrome (MAS) in the history or suspected at screening.
  17. MAS diagnosed within the last 2 months prior to Day 0.
  18. Previous participation in this clinical study if at least one dose of the investigational product has been received.

    • MAS criteria: Fever and hyperferritinemia > 684 ng/mL combined with at least 2/4 criteria:

      • Decreased platelet count ≤181 х 10\^9/L
      • Elevated AST level > 48 U/L
      • Triglyceride elevation >156 mg/dL
      • Decreased fibrinogen ≤ 360 mg/dL Laboratory abnormalities should not be related with other comorbid conditions of the patient, such as immune-mediated thrombocytopenia, infectious hepatitis, visceral leishmaniasis, or familial hyperlipidemia.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    RPH-104

    The investigational product RPH-104 as SC injections at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W).

    Biological: RPH-104

  • Placebo comparator
    Placebo

    placebo SC Q2W (equivalent to investigational product volume)

    Drug: Placebo

Interventions

  • BiologicalRPH-104

    solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

    Also known as: goflikicept, Arcerix

  • DrugPlacebo

    Normal Saline (0.9% Sodium Chloride solution)

06

What researchers measure

Primary outcomes

  1. Time (number of days) to exacerbation during 24 weeks after randomization while taking RPH-104 vs placebo in patients with AOSD

    The criteria for exacerbation are (more than 2 criteria or worsening of more than 2 previous criteria): * fever (body temperature ≥ 38.0 °C) due to AOSD during a week before the visit; * rash typical of AOSD; * clinical disease activity index (CDAI) \> 2.8 for subjects with inactive disease; \> 10 for subjects with low disease activity\*; * sore throat\*; * pericardial effusion ≥ 7 mm\*; * pleuritis\*; * chest pain \> 3 numeric rating scale (NRS)\*; * C-reactive protein (CRP) \> 5 mg/L\*; * aminotransferase (ALT, AST) level \> 3 x upper limits of normal (ULN)\*; * leukocyte count \> 10 x 10\^9/L with \> 80 % polymorphonuclear neutrophils\*; * ferritin level \> 3 x ULN\*; * Patient's Global Assessment (PtGA) worsening by 2 cm and more; * Physician's Global Assessment (PGA) worsening by 2 cm and more; * myalgia\*; * hepatomegaly\*; * splenomegaly\*; * lymphadenopathy\*. \* Increase/presence of noted signs due to other reason than AOSD should not be considered in the activity assessment for AOSD exacerbation.

    Time frame: from randomization (visit 16, week 29) to exacerbation, up to week 53

Secondary outcomes

  1. Proportion of patients from RPH-104 group who developed AOSD exacerbation during 24 weeks after randomization vs placebo

    The criteria for exacerbation are (more than two criteria or worsening of more than two previous criteria): * fever, i. e. body temperature ≥ 38.0 °C due to AOSD lasting at least two consecutive days; * rash typical of AOSD; * sore throat\*; * pericardial effusion ≥ 7 mm\*; * pleuritis\*; * aminotransferase (ALT, AST) level \> 3 x ULN\*; * leukocyte count \> 15 x 10\^9/L\*; * ferritin level \> 3 x ULN\*; * myalgia\*; * hepatomegaly\*; * splenomegaly\*; * lymphadenopathy\*; * pneumonia\*; * arthritis\*. \* Increase/presence of noted signs due to other reason than AOSD should not be considered in the activity assessment for AOSD exacerbation.

    Time frame: up to week 53

  2. Proportion of patients who developed AOSD exacerbation during the run-in period

    The criteria for exacerbation are (more than two criteria or worsening of more than two previous criteria): * fever, i. e. body temperature ≥ 38.0 °C due to AOSD lasting at least two consecutive days; * rash typical of AOSD; * sore throat\*; * pericardial effusion ≥ 7 mm\*; * pleuritis\*; * aminotransferase (ALT, AST) level \> 3 x ULN\*; * leukocyte count \> 15 x 10\^9/L\*; * ferritin level \> 3 x ULN\*; * myalgia\*; * hepatomegaly\*; * splenomegaly\*; * lymphadenopathy\*; * pneumonia\*; * arthritis\*. \* Increase/presence of noted signs due to other reason than AOSD should not be considered in the activity assessment for AOSD exacerbation.

    Time frame: up to week 29

  3. Proportion of patients with fever resolution

    Proportion of patients with fever resolution during the run-in treatment period. Fever resolution means body temperature \< 38.0 °C

    Time frame: up to Day 14

  4. Proportion of patients with Simple disease activity index (SDAI) ≤ 3.3

    Proportion of patients with SDAI ≤ 3.3 during the run-in treatment period. SDAI is the sum of five parameters: * Physician's Global Assessment (PGA) and * Patient's Global Assessment (PtGA) * C-Reactive Protein (CRP) level\* * Number of joints with active arthritis (based on an assessment of 28 joints): Tender Joint Count (TJC) (0-28) + Swollen Joint Count (SJC) (0-28) + PtGA (Visual analogue scale (VAS) in cm) + PGA (VAS) + CRP (mg/dl) The maximum score is 86 with high disease activity (the worst outcome). \*Another cause for the elevated CRP must be ruled out.

    Time frame: up to Day 203

  5. Proportion of patients with CDAI 3.3 - 11

    Proportion of patients with CDAI 3.3 - 11 during the run-in treatment period. CDAI will be calculated using the following formula: CDAI = tender joint number (TJN) (0-28) + swollen joint number (SJN) (0-28) + Patient Global Assessment of Disease Activity (Visual analogue scale (VAS) in cm) + Physician Global Assessment (VAS in cm). CDAI Range: 0 - 76, with a decrease from baseline indicating improvement.

    Time frame: up to Day 203

  6. Proportion of patients with a decrease in modified Pouchot score (mPouchot) score of at least 3 points or a decrease in mPouchot score of at least 1 point, provided that mPouchot score ≤4 at baseline (Day 0), during the run-in treatment period

    mPouchot score is calculated by assigning 1 point to each of these items: * fever (body temperature ≥ 38.0 °C due to AOSD); * rash typical of AOSD (according to data of physical examination); * number of joints with active arthritis (0 to 68/66 joints)\*; * sore throat (according to complaints as of examination)\*; * pericardial effusion (Echocardiography)\*; * pleuritis (ultrasound examination of the lungs)\*; * aminotransferase (ALT, AST) activity\*; * leukocyte count\*; * ferritin level\*; * myalgia (according to complaints as of examination)\*; * hepatomegaly (ultrasound examination of the abdominal organs)\*; * lymphadenopathy (physical examination)\*; * Pneumonia (chest X-ray data)\*. The maximum score is 12 points with high disease activity (the worst outcome). Hepatomegaly and aminotransferase levels are 1 point. * For noted signs, which are not AOSD-specific, other reason for their increase/presence should be considered in the activity assessment for AOSD exacerbation.

    Time frame: up to Day 203

  7. Proportion of patients with clinically significant reduction in joint manifestations

    Proportion of patients with clinically significant reduction in joint manifestations - SDAI reduced by at least 7 points from baseline (Day 0), during the run-in treatment period.

    Time frame: up to Day 203

07

Study locations

4 sites
  • Research Institute of Rheumatology. V.A. Nasonova
    Moscow, 115522, Russian Federation
  • Clinic of Nephrology, Internal and Occupational Diseases. EAT. Tareeva, University Clinical Hospital No. 3
    Moscow, 119991, Russian Federation
  • State Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital, Department of Rheumatology
    St. Petersburg, 194291, Russian Federation
  • FGBU "National Medical Research Center named after V.A. Almazov", Ministry of Health of the Russian Federation, Department of Rheumatology
    St. Petersburg, 197341, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2023; primary completion for Aug 2025, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartEst.
Dec 2023
Primary completionEst.
Aug 2025
CompletionEst.
Aug 2025
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05432960
Collaborators
Exacte Labs LLC, Ministry of Health, Russian Federation, Scientific Center EFiS LLC, Data Management 365
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Dec 2023 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Nov 15, 2024

Study contacts

Mikhail Samsonov
study director · Chief Medical Officer, R-Pharm

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goflikicept

Start the discussion